AbbVie Inc (ABBV)vsPhibro Animal Health Corporation (PAHC)
ABBV
AbbVie Inc
$291.31
+1.07%
HEALTHCARE · Cap: $521.11B
PAHC
Phibro Animal Health Corporation
$32.96
-6.89%
HEALTHCARE · Cap: $1.58B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4248% more annual revenue ($66.01B vs $1.52B). ABBV leads profitability with a 15.7% profit margin vs 6.6%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
PAHC
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.31
$134.02 premium
Margin of Safety
-9.1%
Fair Value
$47.21
Current Price
$32.96
$14.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
Earnings expanding 24.6% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
4.8% revenue growth
Smaller company, higher risk/reward
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : PAHC
The strongest argument for PAHC centers on Return on Equity, P/E Ratio, EPS Growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : PAHC
The primary concerns for PAHC are PEG Ratio, Revenue Growth, Market Cap. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a mature stock while PAHC is a value play — different risk/reward profiles.
PAHC carries more volatility with a beta of 0.42 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 60/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Phibro Animal Health Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?